Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 5
2005 14
2006 9
2007 12
2008 15
2009 13
2010 25
2011 37
2012 28
2013 24
2014 47
2015 41
2016 36
2017 42
2018 34
2019 31
2020 37
2021 45
2022 44
2023 42
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: kim jh. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Circadian Rhythm Sleep-Wake Disorders in Older Adults.
Kim JH, Elkhadem AR, Duffy JF. Kim JH, et al. Sleep Med Clin. 2022 Jun;17(2):241-252. doi: 10.1016/j.jsmc.2022.02.003. Sleep Med Clin. 2022. PMID: 35659077 Free PMC article. Review.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Among authors: kim jh. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Sung C, An J, Lee S, Park J, Lee KS, Kim IH, Han JY, Park YH, Kim JH, Kang EJ, Hong MH, Kim TY, Lee JC, Lee JL, Yoon S, Choi CM, Lee DH, Yoo C, Kim SW, Jeong JH, Seo S, Kim SY, Kong SY, Choi JK, Park SR. Sung C, et al. Among authors: kim jh. Nat Cancer. 2023 Jun;4(6):844-859. doi: 10.1038/s43018-023-00572-5. Epub 2023 Jun 12. Nat Cancer. 2023. PMID: 37308678
Editorial: Insights in learning and memory: 2022.
Kelly ÁM, Manahan-Vaughan D, Kim JH. Kelly ÁM, et al. Among authors: kim jh. Front Behav Neurosci. 2024 Apr 2;18:1399780. doi: 10.3389/fnbeh.2024.1399780. eCollection 2024. Front Behav Neurosci. 2024. PMID: 38628603 Free PMC article. No abstract available.
Deep Brain Stimulation for Addictive Disorders-Where Are We Now?
Yuen J, Kouzani AZ, Berk M, Tye SJ, Rusheen AE, Blaha CD, Bennet KE, Lee KH, Shin H, Kim JH, Oh Y. Yuen J, et al. Among authors: kim jh. Neurotherapeutics. 2022 Jul;19(4):1193-1215. doi: 10.1007/s13311-022-01229-4. Epub 2022 Apr 11. Neurotherapeutics. 2022. PMID: 35411483 Free PMC article. Review.
492 results